This is encouraging, but I am not holding my breath given the relative failure that was MS + Pembro in FORWARD II.
Monotherapy results with Anetumab R. weren't especially good in this indication, only matching chemo although with a much better AE profile. One of the promises of ADCs is that they would be more desirable than chemo in combination therapy because they would spare the immune system and healthy tissues; this seems to be true for MS in combination with most other non-chemo EOC therapies besides Pembro unfortunately.
However, this is a different histology unlike EOC where Pembro monotherapy also seems to work so it's possible the result will be different as well. Keeping my fingers crossed here.